Copyright
©2014 Baishideng Publishing Group Co., Limited. All rights reserved.
World J Diabetes. Feb 15, 2014; 5(1): 52-58
Published online Feb 15, 2014. doi: 10.4239/wjd.v5.i1.52
Published online Feb 15, 2014. doi: 10.4239/wjd.v5.i1.52
Hepatitis C virus infection and insulin resistance
Sandip K Bose, Ranjit Ray, Department of Molecular Microbiology and Immunology, Saint Louis University, St. Louis, MO 63104, United States
Ranjit Ray, Division of Infectious Diseases, Allergy and Immunology, Edward A Doisy Research Center, St. Louis, MO 63104, United States
Ranjit Ray, Department of Internal Medicine, Saint Louis University, St. Louis, MO 63104, United States
Author contributions: Bose SK performed literature search and wrote the initial draft of the paper; Ray R edited the paper and made additional changes as needed.
Supported by The National Institutes of Health, NO. DK080812
Correspondence to: Ranjit Ray, PhD, Division of Infectious Diseases, Allergy and Immunology, Edward A Doisy Research Center, 1100 S. Grand Blvd., 8th Floor, St. Louis, MO 63104, United States. rayr@slu.edu
Telephone: +1-314- 9779034 Fax: +1-314-7713816
Received: November 9, 2013
Revised: December 20, 2013
Accepted: January 13, 2014
Published online: February 15, 2014
Revised: December 20, 2013
Accepted: January 13, 2014
Published online: February 15, 2014
Core Tip
Core tip: Insulin resistance is one of the pathological features in patients with hepatitis C virus (HCV) infection and often leads to development of type II diabetes. Recent evidence indicates that HCV associated insulin resistance may result in hepatic fibrosis, steatosis, hepatocellular carcinoma and resistance to anti-viral treatment. In this review, we summarize the available information on how HCV infection interferes with insulin signaling pathways.